Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PQTVF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-PRLR-Ab-LP1-P3
|
|||||
| Synonyms |
Anti-PRLR-Ab LP1 P3
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Autoimmune disorder [ICD11:4A41-4A4Z]
Investigative
Immune dysregulation syndrome [ICD11:4A01]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-PRLR mAb
|
Antibody Info | ||||
| Antigen Name |
Prolactin receptor (PRLR)
|
Antigen Info | ||||
| Payload Name |
Budesonide derivative P3
|
Payload Info | ||||
| Therapeutic Target |
Glucocorticoid receptor (NR3C1)
|
Target Info | ||||
| Linker Name |
DIBAC-suc-PEG4-Val-Cit-PAB
|
Linker Info | ||||
| Conjugate Type |
The conjugation is microbial transglutaminase (MTG)-mediated attachment of linker to the antibodies. Site-specific conjugations were performed using N297Q-mutated antibody.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.